Objective The aim of the study was to assess whether azathioprine and antitumour necrosis factor (TNF) treatment decrease the long-term need for surgery in patients with Crohn's disease.
Methods This was an observational study of a referral centre cohort. The cumulative incidence of the first Crohn's disease-related major abdominal surgery was estimated using the Kaplan–Meier method, and independent predictors of surgery were identified using Cox proportional hazards regression with propensity scores adjustment. Receiver operating characteristic (ROC) analysis was used to identify optimal cut-offs for duration of maintenance treatments. The electronic charts of 296 incident cases of Crohn's disease from Nancy University Hospital, France, diagnosed between 2000 and 2008, were reviewed through January 2010.
Results The median follow-up time per patient was 57 months. Seventy-six patients (26%) underwent at least one major abdominal surgical procedure. The cumulative probabilities of the first Crohn's disease-related major abdominal surgery were 6.5, 25.9 and 44.3 at 1, 5 and 9 years, respectively. In the ROC analysis, the duration of anti-TNF and azathioprine treatment had significant cut-off values (≤475 days ∼16 months and ≤45 days ∼1.5 months, respectively) with positive likelihood ratios (PLRs) of 1.52 (p<0.0001) and 1.51 (p=0.003) for the first Crohn's disease-related major abdominal surgery. Using multivariate Cox proportional hazards regression analysis (after propensity score adjustment), independent positive predictors of major abdominal surgery were stricturing (HR=12.01; 95% CI 5.97 to 24.17) or penetrating (HR=10.77; 95% CI 4.87 to 23.80) disease behaviour at diagnosis, duration of anti-TNF treatment of <16 months (HR=3.86; 95% CI 1.77 to 8.45) and duration of azathioprine treatment of <1.5 months (HR=2.00; 95% CI 1.20 to 3.34).
Conclusions Non-complicated inflammatory disease behaviour and long-term anti-TNF treatment are associated with a lower risk for surgery whereas azathioprine only modestly lowers this risk.
- Crohn's disease-related surgery
- tumour necrosis factor antagonists
- IBD clinical
- surgery for IBD
Statistics from Altmetric.com
Funding LPB has received consulting fees from Abbott Laboratories and UCB Pharma; lecture fees from speaking at continuing medical education events from Centocor; and grant support from UCB Pharma.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.